Core Viewpoint - Enhabit (EHAB) reported quarterly earnings of $0.14 per share, matching the Zacks Consensus Estimate, and showing a significant increase from $0.04 per share a year ago, indicating a positive earnings surprise of +3.70% [1] Financial Performance - Enhabit achieved revenues of $270.4 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.40%, and up from $258.2 million in the same quarter last year [2] - The company has exceeded consensus EPS estimates in all four of the last quarters [2] Stock Performance - Enhabit shares have increased approximately 47.5% since the beginning of the year, contrasting with a 0.4% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $264.97 million, and for the current fiscal year, it is $0.56 on revenues of $1.09 billion [7] - The trend of estimate revisions for Enhabit was favorable prior to the earnings release, suggesting potential for continued positive performance [6] Industry Context - The Medical Services industry, to which Enhabit belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.62%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.63 per share when it actually produced earnings of $0.67, delivering a surprise of +6.35%.Over the last four quarters, the compan ...

Core Insights - Enhabit reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, and showing significant growth from $0.03 per share a year ago, resulting in an earnings surprise of +41.67% [1] - The company generated revenues of $263.6 million for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.74%, but up from $253.6 million year-over-year [2] - Enhabit has surpassed consensus EPS estimates three times over the last four quarters, but has only topped revenue estimates once in the same period [2] Financial Performance - The earnings surprise of +41.67% indicates strong performance relative to expectations, while the revenue miss suggests challenges in meeting market forecasts [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.13, with projected revenues of $271.08 million, and for the current fiscal year, the EPS estimate is $0.49 on revenues of $1.06 billion [7] Market Position - Enhabit shares have increased by approximately 4.4% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.1% [3] - The Zacks Rank for Enhabit is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical Services industry, to which Enhabit belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential headwinds for stock performance [8] - The performance of Enhabit may be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

分组1 - Enhabit reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.07 per share a year ago, resulting in an earnings surprise of +30.00% [1] - The company posted revenues of $266.1 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.14%, and showing an increase from $260.6 million year-over-year [2] - Enhabit shares have underperformed the market, losing about 14.3% since the beginning of the year compared to the S&P 500's gain of 7.1% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.11 on revenues of $266.82 million, and for the current fiscal year, it is $0.44 on revenues of $1.06 billion [7] - The Medical Services industry, to which Enhabit belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Auna S.A., another company in the same industry, is expected to report quarterly earnings of $0.16 per share, reflecting a year-over-year change of +433.3%, with revenues expected to be $314.67 million, up 7.8% from the previous year [9]

Core Viewpoint - Enhabit (EHAB) reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.07 per share, marking a 42.86% earnings surprise compared to the previous year's earnings of $0.07 per share [1] Financial Performance - Enhabit posted revenues of $259.9 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.56% and down from $262.4 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Stock Performance - Enhabit shares have increased by approximately 2.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $267.14 million, and for the current fiscal year, it is $0.37 on revenues of $1.07 billion [7] - The estimate revisions trend for Enhabit is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Enhabit belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]